Mostrar el registro sencillo del ítem
dc.contributor.author
Chandran, Mayuri
dc.contributor.author
Candolfi, Marianela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Shah, Diana
dc.contributor.author
Mineharu, Yohei
dc.contributor.author
Yadav, Viveka Nand
dc.contributor.author
Koschmann, Carl
dc.contributor.author
Asad, Antonela Sofía
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Lowenstein, Pedro R.
dc.contributor.author
Castro, Maria Gabriela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2018-12-20T17:53:39Z
dc.date.issued
2017-05
dc.identifier.citation
Chandran, Mayuri; Candolfi, Marianela; Shah, Diana; Mineharu, Yohei; Yadav, Viveka Nand; et al.; Single vs. combination immunotherapeutic strategies for glioma; Informa Healthcare; Expert Opinion on Biological Therapy; 17; 5; 5-2017; 543-554
dc.identifier.issn
1471-2598
dc.identifier.uri
http://hdl.handle.net/11336/66841
dc.description.abstract
Introduction: Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). Precision immunotherapies or combinations of immunotherapies that target unique tumor-specific features may substantially improve upon existing treatments. Areas covered: Clinical trials of single immunotherapies have shown therapeutic potential in high-grade glioma patients, and emerging preclinical studies indicate that combinations of immunotherapies may be more effective than monotherapies. In this review, the authors discuss emerging combinations of immunotherapies and compare efficacy of single vs. combined therapies tested in preclinical brain tumor models. Expert opinion: Malignant gliomas are characterized by a number of factors which may limit the success of single immunotherapies including inter-tumor and intra-tumor heterogeneity, intrinsic resistance to traditional therapies, immunosuppression, and immune selection for tumor cells with low antigenicity. Combination of therapies which target multiple aspects of tumor physiology are likely to be more effective than single therapies. While a limited number of combination immunotherapies are described which are currently being tested in preclinical and clinical studies, the field is expanding at an astounding rate, and endless combinations remain open for exploration.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Informa Healthcare
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
Cancer Vaccines
dc.subject
Gene Therapy
dc.subject
Glioma
dc.subject
Immune Checkpoint Blockade
dc.subject
Immunotherapy
dc.subject.classification
Inmunología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Básica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Single vs. combination immunotherapeutic strategies for glioma
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-10-23T19:48:58Z
dc.identifier.eissn
1744-7682
dc.journal.volume
17
dc.journal.number
5
dc.journal.pagination
543-554
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Londres
dc.description.fil
Fil: Chandran, Mayuri. University of Michigan; Estados Unidos
dc.description.fil
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Shah, Diana. University of Michigan; Estados Unidos
dc.description.fil
Fil: Mineharu, Yohei. Kyoto University; Japón
dc.description.fil
Fil: Yadav, Viveka Nand. University of Michigan; Estados Unidos
dc.description.fil
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
dc.description.fil
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
dc.description.fil
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
dc.journal.title
Expert Opinion on Biological Therapy
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451096/
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/14712598.2017.1305353
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1305353
Archivos asociados